Cargando…

The frequency and availability of population-specific patient reported outcome measures and minimal clinically important differences among approved drugs in Canada

BACKGROUND: Patient reported outcome measures (PROMs) and minimal clinically important differences (MCIDs) are included in Canada’s Common Drug Review (CDR) process to approve new drugs. Often, the measures report on the health-related quality of life (HRQoL), but can also describe the symptoms, eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soprovich, Allison, Ingstrup, Meghan, Eurich, Dean T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322322/ https://www.ncbi.nlm.nih.gov/pubmed/30616654 http://dx.doi.org/10.1186/s12955-018-1070-0

Ejemplares similares

An analysis of redactions in Canada’s Common Drug Review Clinical Review Reports and how they relate to the patients’ voice
por: Soprovich, Allison, et al.
Publicado: (2017)

Adopting and implementing an innovative model to organize diabetes care within First Nations communities: A qualitative assessment
por: Wozniak, Lisa A., et al.
Publicado: (2021)

Mental health experiences with COVID-19 public health measures in an Alberta First Nations Community
por: Lee, Cerina, et al.
Publicado: (2022)

Support for healthcare workers and patients after medical error through mutual healing: another step towards patient safety
por: Aubin, Diane Louise, et al.
Publicado: (2022)

Completion of multiple-dose travel vaccine series and the availability of pharmacist immunizers: A retrospective analysis of administrative data in Alberta, Canada
por: Houle, Sherilyn K. D., et al.
Publicado: (2019)

Appropriateness of COVID-19 public health guidelines for an Alberta First Nations community
por: Soprovich, Allison L., et al.
Publicado: (2022)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
por: Herring, Shawn, et al.
Publicado: (2021)

Addressing the gaps in diabetes care in first nations communities with the reorganizing the approach to diabetes through the application of registries (RADAR): the project protocol
por: Eurich, Dean T., et al.
Publicado: (2017)

Health Canada approves first drug for treatment of COVID-19
Publicado: (2020)

Effectiveness of RADAR: An Innovative Model to Organize Diabetes Care in First Nations Communities
por: Eurich, Dean T., et al.
Publicado: (2023)

Comparison of drug coverage in Canada before and after the establishment of the pan-Canadian Pharmaceutical Alliance
por: Milliken, Debbie, et al.
Publicado: (2015)

Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study
por: Sharma, Vishal, et al.
Publicado: (2019)

Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different
por: LaHood, Allison, et al.
Publicado: (2022)

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997–2012
por: Herder, Matthew, et al.
Publicado: (2016)

Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021)

Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
por: Gaudette, Étienne, et al.
Publicado: (2023)

Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study
por: Sharma, Vishal, et al.
Publicado: (2020)

How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014)

Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
por: Fadaleh, Sarah Abu, et al.
Publicado: (2020)

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
por: Davis, Courtney, et al.
Publicado: (2017)

Radiation Oncology Device Approval in the United States and Canada
por: Beers, Craig A, et al.
Publicado: (2019)

The need to streamline approval processes for clinical research in Canada
por: Lumia, Celeste M., et al.
Publicado: (2023)

Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
por: Miller, Jennifer E., et al.
Publicado: (2021)

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2016)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
por: Mansell, Kerry, et al.
Publicado: (2019)

Invasive Pneumococcal Disease and Long-Term Mortality Rates in Adults, Alberta, Canada
por: Versluys, Kristen A., et al.
Publicado: (2022)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
por: Mansell, Kerry, et al.
Publicado: (2019)

Men’s Physical Activity and Sleep Following a Workplace Health Intervention: Findings from the POWERPLAY STEP Up challenge
por: Seaton, Cherisse L., et al.
Publicado: (2021)

An intergenerational study of perceptions of changes in active free play among families from rural areas of Western Canada
por: Holt, Nicholas L., et al.
Publicado: (2016)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
por: McPhail, Melanie, et al.
Publicado: (2022)

Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability
por: Almajed, Suaad, et al.
Publicado: (2021)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Exploring the impact of pharmacist comprehensive annual care plans on perceived quality of chronic illness care by patients in Alberta, Canada
por: Necyk, Candace, et al.
Publicado: (2021)

Assessing responsiveness of generic and specific health related quality of life measures in heart failure
por: Eurich, Dean T, et al.
Publicado: (2006)

The use of patient-reported outcome measures in primary care: applications, benefits and challenges
por: Brower, Krista, et al.
Publicado: (2021)

Measuring the frequency and variation of unnecessary care across Canada
por: Bouck, Zachary, et al.
Publicado: (2019)

Measuring organizational mentoring climate: Importance and availability scales
por: Tigges, Beth B., et al.
Publicado: (2020)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qbp5laib9j2ohe7gkfgdvahhlu